Search results
Results From The WOW.Com Content Network
Pages in category "Pharmaceutical companies of Portugal" The following 3 pages are in this category, out of 3 total. This list may not reflect recent changes. B.
Bial (Portela e C.ª, S.A.) is a pharmaceutical company headquartered in São Mamede do Coronado, in Trofa, Porto district, Portugal. It was founded in 1924, being among the largest companies of its kind in Portugal. Its products are sold in pharmacies in more than 58 countries in 4 continents: Europe, America, Africa and Asia.
The drug policy of Portugal, informally called the "drug strategy", was put in place in 2000, and came into effect in July 2001.Created by the Decree-Law n. 130 -A/2001 and under the jurisdiction of the Commissions for the Dissuasion of Drug Addiction, [1] its purpose was to reduce the number of new HIV/AIDS cases in the country, as it was estimated around half of new cases came from injection ...
The presented data highlights the high challenges created by metabolic risk factors, including high blood pressure, high blood sugar, and obesity, which have been contributing to the GBD in Portugal. The data provides deep insights of mortality, life expectancy, and health trends, helping to develop public health strategies aimed at reducing ...
Bluepharma (full name Bluepharma — Indústria Farmacêutica, SA) is a pharmaceutical company of Portuguese ownership, which is located in Coimbra, Portugal. Bluepharma became FDA approved since 2009 for the development of solid pharmaceutical forms, "becoming the first Portuguese pharmaceutical company to export to the US market." [1]
Risk management is most effective once the motivation behind the behavior of disposing unused pharmaceuticals is understood. There was little correlation found between the perception of risk and knowledge regarding pharmaceutical waste according to a study conducted by Cook and Bellis in 2001. [ 36 ]
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by the British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. [1]
The companies involved included Alpha Therapeutic Corporation, Institut Mérieux (which then became Rhone-Poulenc Rorer Inc., and is now part of Sanofi), Bayer Corporation and its Cutter Biological division, and Baxter International and its Hyland Pharmaceutical division. [2]